Renal anaemia: recent developments, innovative approaches and future directions for improved management.
The morbidity, mortality and economic burden of chronic kidney disease (CKD) and associated anaemia are substantial. With the increasing numbers of patients who are likely to be affected in the future, approaches are required to improve anaemia management without increasing the burden on health-care professionals. A multidisciplinary approach to treatment, where early initiation of erythropoiesis-stimulating agents (ESA) is encouraged, may improve patient outcomes. Recent studies also suggest that the early use of iron therapy in patients with CKD not on dialysis may be associated with beneficial effects on haemoglobin levels. Another strategy to reduce the burden on health-care providers is to simplify anaemia management by extending the administration interval of ESA. Indeed, recent studies have explored the efficacy of extending the administration interval of ESA in clinical practice in CKD patients on dialysis and not on dialysis. The ability to maintain haemoglobin levels within guideline ranges at extended administration intervals may improve patient care and reduce the workload of health-care providers.
Kerr
Peter G
PG
Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia. peter.kerr@med.monash.edu.au
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D009398:Nephrology / Q000639:trends; D011994:Recombinant Proteins; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000401:mortality
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron